FANJ
NKTR icon

Financial Architects (New Jersey)’s Nektar Therapeutics NKTR Stock Holding History

Financial Architects (New Jersey)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200
Closed -$318K – 1440
2018
Q1 		$318K Buy
+200
New +$258K 0.06% 218

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Financial Architects (New Jersey)'s NKTR Position: Q3 2020 in Review

Financial Architects (New Jersey) sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 73 shares — an estimated $25K sold.

Financial Architects (New Jersey) first reported a position in NKTR in Q2 2013 and held it in 20 quarters. The position peaked at $262K in Q1 2018. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Financial Architects (New Jersey) reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 73 Nektar Therapeutics shares in Q3 2020, an estimated $25K.
  • Financial Architects (New Jersey) first reported a position in Nektar Therapeutics in Q2 2013 and held it in 20 quarters.
  • Financial Architects (New Jersey)'s Nektar Therapeutics position peaked at $262K in Q1 2018.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2020, filed 9 Nov 2020.